Clonazepam detailed information

Clonazepam detailed information

Clinical data
Pregnancy category	AU: C US: D (Evidence of risk)
Routes of administration	Oral, I.M., I.V, sublingual
ATC code	N03AE01 (WHO)
Legal status
Legal status	US: Schedule IV
Pharmacokinetic data
Bioavailability	90%
Metabolism	Hepatic CYP3A4
Elimination half-life	18–50 hours
Excretion	Renal
Identifiers
IUPAC name 6-(2-chlorophenyl)-9-nitro- 2,5-diazabicyclo[5.4.0]undeca- 5,8,10,12-tetraen-3-one
CAS Number	1622-61-3
PubChem CID	2802
DrugBank	APRD00054
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H10ClN3O3
Molar mass	315.715

WikiDoc Resources for Clonazepam detailed information
Articles
Most recent articles on Clonazepam detailed information Most cited articles on Clonazepam detailed information Review articles on Clonazepam detailed information Articles on Clonazepam detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Clonazepam detailed information Images of Clonazepam detailed information Photos of Clonazepam detailed information Podcasts & MP3s on Clonazepam detailed information Videos on Clonazepam detailed information
Evidence Based Medicine
Cochrane Collaboration on Clonazepam detailed information Bandolier on Clonazepam detailed information TRIP on Clonazepam detailed information
Clinical Trials
Ongoing Trials on Clonazepam detailed information at Clinical Trials.gov Trial results on Clonazepam detailed information Clinical Trials on Clonazepam detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Clonazepam detailed information NICE Guidance on Clonazepam detailed information NHS PRODIGY Guidance FDA on Clonazepam detailed information CDC on Clonazepam detailed information
Books
Books on Clonazepam detailed information
News
Clonazepam detailed information in the news Be alerted to news on Clonazepam detailed information News trends on Clonazepam detailed information
Commentary
Blogs on Clonazepam detailed information
Definitions
Definitions of Clonazepam detailed information
Patient Resources / Community
Patient resources on Clonazepam detailed information Discussion groups on Clonazepam detailed information Patient Handouts on Clonazepam detailed information Directions to Hospitals Treating Clonazepam detailed information Risk calculators and risk factors for Clonazepam detailed information
Healthcare Provider Resources
Symptoms of Clonazepam detailed information Causes & Risk Factors for Clonazepam detailed information Diagnostic studies for Clonazepam detailed information Treatment of Clonazepam detailed information
Continuing Medical Education (CME)
CME Programs on Clonazepam detailed information
International
Clonazepam detailed information en Espanol Clonazepam detailed information en Francais
Business
Clonazepam detailed information in the Marketplace Patents on Clonazepam detailed information
Experimental / Informatics
List of terms related to Clonazepam detailed information

Clonazepam (marketed by Roche under the trade-names Klonopin in the United States and Rivotril in Europe, South America, Canada, India, and Australia) is a drug which is a benzodiazepine derivative. It is a highly potent anticonvulsant, amnestic, anxiolytic and muscle relaxant. Clonazepam is also used in cases of amphetamine overdose as to reverse some of the adverse effects.

Pharmacology

Clonazepam is a chlorinated derivative of nitrazepam. Clonazepam is classed as a nitrobenzodiazepine along with nitrazepam and flunitrazepam. Aromatic nitro-containing compounds such as clonazepam produce superoxide free radicals during cellular metabolism by endothelial cells. The nitro anion radical produced during clonazepam metabolism rapidly reacts with oxygen to form the free radical superoxide.

Clonazepam is chemically related to quinazolines and is a hapten. Like other benzodiazepines, clonazepam acts on benzodiazepine receptors which enhance the binding of GABA to the GABA_A receptor which results in inhibitory effects on the central nervous system. Because of its powerful anxiolytic properties, it is said to be among the class of "highly potent" benzodiazepines. Although benzodiazepines are valuable in the treatment of anxiety disorders, they carry a high potential for physical and psychological dependence with profound withdrawal symptoms, especially if discontinued abruptly or overrapidly in certain individuals. Caution is advised when taking this or any benzodiazepine medication longer than a few weeks.

One milligram of clonazepam is approximately equivalent to twenty milligrams of diazepam.

Clonazepam appears to also have a secondary effect on the neurotransmitter serotonin. It has shown itself to be highly effective as a short-term (3 weeks) adjunct to SSRI treatment in obsessive-compulsive disorder and clinical depression in reducing SSRI side effects with the combination being superior to SSRI treatment alone in a study funded by the manufacturers of clonazepam, Hoffman LaRoche Inc. Similar results have been found with some other anxiety disorders, but the role of the serotonergic effects enhancing the action of the SSRI treatment remains unclear in these cases due to clonazepam's primary anxiolytic mechanism of action.

The anticonvulsant properties of clonazepam and other benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.

Peak blood concentrations of 6.5–13.5 ng/mL were usually reached within 1–2 hours following a single 2 mg oral dose of micronized clonazepam in healthy adults. In some individuals, however, peak blood concentrations were reached at 4–8 hours.

Indications

Clonazepam is sometimes used for refractory epilepsies; however, long-term prophylactic treatment of epilepsy has considerable limitations, most notably the loss of antiepileptic effects due to tolerance, which renders the drug useless with long-term use, and also side effects such as sedation, which is why clonazepam and benzodiazepines as a class should generally only be prescribed for the acute management of epilepsies. Clonazepam is less effective and potent as an anticonvulsant in bringing infantile seizures under control compared with nitrazepam in the treatment of West syndrome, which is an age-dependent epilepsy affecting the very young. However, as with other epilepies treated with benzodiazepines, long-term therapy becomes ineffective with prolonged therapy, and the side effects of hypotonia and drowsiness are troublesome with clonazepam therapy; other antiepileptic agents are therefore recommended for long-term therapy, possibly Corticotropin (ACTH) or vigabatrin. Clonazepam is therefore not recommended for widespread use in the management of seizures related to West syndrome. Also with long-term use, abrupt or overrapid withdrawal from clonazepam can precipitate withdrawal-related seizures if tolerance and physical dependence have developed.

Clonazepam has been used in the management of seizure disorders in children and also for infantile spasms. However, usefulness of clonazepam is limited due to its deleterious effect on neurological function, especially its negative effect on cognition. Clobazam, a 1,5-benzodiazepine, has shown to be less neurotoxic than 1,4-benzodiazepines such as clonazepam.

Clonazepam may be prescribed for:

• Epilepsy
• Anxiety disorders
• Panic attacks due to the often chronic nature of panic disorders, long-term therapy may be advocated. SSRIs are considered the primary drug, along with cognitive-behavioral therapy, with
• Initial treatment of mania, together with firstline drugs such as lithium, haloperidol or risperidone
• Restless legs syndrome

Clonazepam is rarely used as a treatment for insomnia due to its relatively weak hypnotic effects. It has not been marketed for the treatment of insomnia mainly because its long half life makes it unsuitable for this application.

Availability

File:Klonopin0.5mg.jpg

Klonopin 0.5 mg

File:Klonopin1mg.jpg

Klonopin 1 mg

File:Clonazepam1mg.png

Clonazepam 1 mg (Generic)

File:Clonazepam2mg DOJ.jpg

Clonazepam was approved in the United States as a generic drug in 1997 and is now manufactured and marketed by several companies.

Clonazepam is available in the U.S. as tablets (0.5, 1.0, and 2 mg), orally disintegrating tablets (wafers) (0.125, 0.25, 0.5, 1.0, and 2 mg), liquid solutions (2.5 mg/mL) and for injection (1 mg/mL)

Like all benzodiazepines, clonazepam is a benzodiazepine receptor agonist. Long-term use (more than 2–4 weeks) can lead to a number of problems, including muscle weakness and fatigue, tolerance, physical dependence and withdrawal syndromes upon discontinuation. The benzodiazepine withdrawal syndrome, which may appear during reduction or withdrawal of clonazepam treatment, can be reduced in intensity with gradual reduction of dosage. Clonazepam is sometimes used to help with Methadone withdrawal symptoms

Side effects

Common:

• Drowsiness
• Impairment of cognition and judgment
• Impaired motor function
  • Impaired coordination
  • Impaired balance
  • Dizziness
• Anterograde amnesia (common with higher doses)

Rare:

• Paradoxical disinhibition (most frequently in children, the elderly, and in persons with developmental disabilities)
  • Rage
  • Excitement
  • Irritability
  • Impulsivity
  • Some users report hangover-like symptoms of being drowsy, having a headache, being sluggish, and being irritable after waking up if the medication is taken before sleep. This is likely the result of the medication's long half-life, which continues to affect the user after waking up, as well as its disruption of the REM cycle.

Withdrawal-related:

• Anxiety, irritability, insomnia
• Panic attacks, tremor
• Seizures similar to delirium tremens (with long-term use of excessive doses)

Many individuals treated on a long-term basis develop a form of dependence known as "low-dose dependence", as was shown in one double-blind, placebo-controlled study of 34 therapeutic low-dose benzodiazepine users—physiological dependence was demonstrated via flumazenil-precipitated withdrawal. Use of alcohol or other CNS depressants while taking clonazepam greatly intensifies the effects (and side effects) of the drug. Side effects of the drug itself are generally benign, but sudden withdrawal after long-term use can cause severe, even fatal, symptoms.

Special precautions

Caution in the Elderly. Increased risk of impairments, falls and drug accumulation.

Caution in children. Clonazepam is not recommended for use in those under 18. Use in very young children may be especially hazardous. Clonazepam was implicated along with the drugs diphenylhydantoin and nitrazepam in the death of a 7 and a half month old girl. She developed inclusions consisting of lamellar profiles, situated in membrane-bound cytosomes which were found mainly in astrocytes, but also in neurones and in axons of peripheral nerves before dying. Lipofuscin bodies were also found to be increased in number.

Protracted withdrawal

10–15% of individuals treated with clonazepam on a long-term basis (in excess of 30 days of continuous use) develop a protracted withdrawal syndrome. Protracted withdrawal lasts for months, years, or a lifetime after clonazepam is discontinued. Protracted withdrawal results from structural brain damage, which is often irreversible. Common protracted withdrawal symptoms include:

• Anxiety
• Insomnia
• Depression
• Tinnitus
• Tingling and numbness in limbs
• Muscle pain and tension
• Weakness
• Cramps
• Tremors
• Irritable bowel
• Cognitive dysfunction

Benzodiazepines including clonazepam may inhibit the glucuronidation of morphine leading to increased levels of and prolongation of the effects of morphine. Clonazepam may inhibit morphine metabolism more than any other benzodiazepine.

Pregnancy

There is some medical evidence of various malformations eg cardiac or facial deformations when used in early pregnancy, however the data is not conclusive. The data is also inconclusive whether benzodiazepines such as clonazepam cause developmental deficits or decreases in IQ when taken during pregnancy. Clonazepam when used late in pregnancy may result in the development of a severe benzodiazepine withdrawal syndrome in the neonate and also floppy infant syndrome. Withdrawal symptoms from benzodiazepines in the neonate may include hypotonia, and reluctance to suck, to apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. These symptoms may persist for hours or months after birth.

Overdose

An individual who has consumed too much clonazepam will display one or more of the following symptoms:

• Somnolence (difficulty staying awake)
• Mental confusion
• Hypotension
• Impaired motor functions
  • Impaired reflexes
  • Impaired coordination
  • Impaired balance
  • Dizziness
• Coma

Unless combined with other drugs, deep coma or other manifestations of severe central nervous system depression are rare, and the mortality rate associated with poisoning is very low. As with other benzodiazepines, overdose symptoms of clonazepam may be reversed with flumazenil (Romazicon®).

Recreational use and abuse

Relatively few cases of addiction arise from legitimate use of benzodiazepines. If in tablet form, they are most commonly used as a secondary drug to increase the pleasure resulting from a primary drug, or to lessen or prevent some of the primary drug's negative side effects. Clonazepam has been implicated in drug facilitated sexual assaults.

External links

• Wallace, Christina. "Kpin, a hit drug with teens, can be deadly, officials say." Boston Metro, Wednesday April 12, 2006. Page 2.
• Carlos, Jean-Marc: The Treatment of Panic Disorder http://www.medscape.com/viewarticle/497207
• Rx-List - Clonazepam
• Poisons Information Monograph - Clonazepam
• FDA prescription insert